Stock NRBO NEUROBO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News NeuroBo Pharmaceuticals, Inc.

Equities

NRBO

US64132R4048

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
3.96 USD -0.88% Intraday chart for NeuroBo Pharmaceuticals, Inc. +4.76% +7.13%
May. 09 NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 08 Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NEUROBO PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
AQ
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target
MT
NEUROBO TO PRESENT LATEST PRE-CLINICAL DATA ON CARDIOMETABOLIC ASSETS, DA-1241 AND DA-1726, TARGETING MASH AND OBESITY, AT SCIENTIFIC CONFERENCES IN JUNE
AQ
Sector Update: Health Care Stocks Mixed Wednesday Afternoon
MT
NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise
MT
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
PR
NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity
CI
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
PR
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash
CI
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
PR
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
NeuroBo Pharmaceuticals to Continue Trial of Liver Disease Treatment Candidate -- Shares Down
MT
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
PR
NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash
CI
NeuroBo Pharmaceuticals Names Marshall Woodworth Finance Chief
MT
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
PR
NeuroBo Pharmaceuticals, Inc. Announces the Appointment of Marshall Woodworth as Chief Financial Officer
CI
NeuroBo Pharmaceuticals : Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer - Form 8-K
PU
NeuroBo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NRBO Stock
  4. News NeuroBo Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW